Health ProductsDear Healthcare Professional Letter

IXIARO Japanese Encephalitis Vaccine (inactivated, adsorbed) - Recall of Lot JEV09L37C - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Biologic/vaccine
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Introduction

This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Details

Health Canada Endorsed Important Safety Information on IXIARO Japanese Encephalitis Vaccine (inactivated, adsorbed)

March 8, 2011

Subject: RECALL of Lot JEV09L37C IXIARO® Japanese Encephalitis vaccine (inactivated, adsorbed)

Dear Health Care Professional,

Intercell AG and Novartis Pharmaceuticals Canada Inc. (Novartis), in consultation with Health Canada, are asking Canadian health care professionals to immediately stop using lot JEV09L37C of IXIARO® (Japanese Encephalitis vaccine (inactivated, adsorbed)), DIN 02333279, UPC Code 0 63601 18546 0.

  • Do not continue to use IXIARO® lot JEV09L37C, as immune response beyond December 23, 2010 is currently unknown.
  • For individuals who are likely to be at risk of exposure to Japanese Encephalitis and were administered a dose of IXIARO® from the affected lot, please be advised of the following recommendations:
    • Subjects having started their primary series with a first dose of IXIARO® lot JEV09L37C before 23 December 2010, but not having received the second dose: complete schedule with a single shot from a different lot of IXIARO®.
    • Subjects having received their second dose or both doses from IXIARO® lot JEV09L37C after 23 December 2010: administer one additional IXIARO® vaccination from a different lot of IXIARO®.
  • Information from clinical trials, though limited, does not indicate any specific safety concern for vaccinees receiving more than two doses within a short period of time.
  • There is no evidence of a safety concern with this lot.

Following a review of potency tests at the 11-month stability time point for lot JEV09L37C, Intercell AG and Novartis, in consultation with Health Canada, have concluded that this specific lot, when administered after December 23, 2010 may be less potent and not induce a full protective immune response in vaccinees. Therefore, lot JEV09L37C IXIARO® is being recalled in Canada.

Consistent with this decision to recall lot JEV09L37C IXIARO®, Novartis is asking Canadian health care professionals and distributors to return any unused doses of IXIARO® from lot JEV09L37C for suitable credit.

Lot JEV09L37C IXIARO® met all quality specifications at time of release and, with the exception of the potency test, all other stability tests were within the requirements. No other lots of IXIARO® are affected by this recall.

Customers who currently have inventory of lot JEV09L37C IXIARO® are advised:

  • Not to administer further doses of lot JEV09L37C IXIARO®
  • To return any unused doses of lot JEV09L37C IXIARO® to CLS Med-Turn International according to directions in the form. New supply is available and free replacement product is available up to the 30th April 2011. Please complete the forms to obtain a credit. For a copy of the forms, please contact Novartis Pharmaceuticals Canada Inc.

IXIARO® is manufactured by Intercell AG and distributed in Canada by Novartis. Intercell AG and Novartis reiterate their commitment to the delivery of quality pharmaceutical products.

Managing marketed health product-related adverse reactions is dependent upon health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse events in patients receiving IXIARO® should be reported to your local public health authorities. Reports may also be sent directly to the Public Health Agency of Canada or Novartis or Health Canada at the following addresses:

Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.,
Dorval, QC H9S 1A9
e-mail address: drug.safety@novartis.com

Public Health Agency of Canada
Vaccine Safety Section
130 Colonnade Road,
Address Locator: 6502A
Ottawa, ON K1A OK9
Telephone: 1-866-844-0018
Fax: 1- 866-844-5931
caefi@phac-aspc.gc.ca

How to report a suspected Adverse Event following Immunization:
If a patient experiences an adverse event following immunization, please complete the Adverse Events Following Immunization (AEFI) Form and send it to the local health department in your province or territory. The list of contacts is also provided below.

If you have any questions or have difficulties contacting your local health department, please contact the Vaccine Safety Section at the Public Health Agency of Canada at:

Telephone: 613-954-5590, 1-866-844-0018
Fax: 613-954-9874; 1-866-844-5931

You can also report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

  • Report online at MedEffectTM Canada Web site
  • Call toll-free at 1-866-234-2345
  • Complete a Reporting Form and:
    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program
      Health Canada
      Postal Locator 0701E
      Ottawa, Ontario K1A 0K9

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.

For other health product inquiries related to this communication, please contact Health Canada at:
Biologics and Genetic Therapies Directorate (BGTD)
E-mail: BGTD_ORA_Enquiries@hc-sc.gc.ca
Telephone: 613-957-1722

To change your mailing address or fax number, contact the Market Authorization Holder (Industry).

We regret any inconvenience this might cause, however, should you have any questions regarding returns, your account or to place an order, please contact Novartis Customer Relations at 1-800-465-2244

Should you require additional medical information regarding the use of IXIARO®, please contact Novartis Medical Information at 1-800-363-8883

Sincerely,

original signed by

Kerstin Westritschnig, M.D.
Medical Officer
Intercell AG

Jean-Marie Leclerc, M.D., FRCP(C)
Chief Scientific Officer and Senior Vice-President
Clinical and Regulatory Affairs
Novartis Pharmaceuticals Canada Inc.

IXIARO® is a registered trademark.

Provincial/Territorial Contacts for Adverse Events Following Immunization Form

  • Alberta
    Alberta Health and Wellness
    Community Health Branch
    Immunization Program
    10025 Jasper Ave NW
    PO Box 1360
    Edmonton, AB T5J 2N3
    Phone: 780-415-2824
    Web site: www.albertahealthservices.ca/
  • British Columbia
    BC Centre for Disease Control
    Epidemiology Services
    655 West 12th Avenue
    Vancouver, BC, V5Z 4R4
    Phone: 604-707-2517
    Fax: 604-707-2516
    Web site: www.bccdc.ca
  • Manitoba
    Manitoba Health & Healthy Living
    Communicable Disease Control Branch
    4th Floor-300 Carlton Street
    Winnipeg, MB R3B 3M9
    Phone: 204-788-6737 Fax: 204-948-3044
    Web site: www.gov.mb.ca/health/publichealth/sri/docs/aefi_form.pdf
  • New Brunswick
    Office of the Chief Medical Officer of Health
    P.O. Box 5100, Carleton Place
    Fredericton, NB E3B 5G8
    Phone: 506-453-2323
    Web site: http://www.gnb.ca/0051/0053/index-e.asp
  • Newfoundland and Labrador
    Public Health
    Dept. of Health and Community Services
    PO Box 8700
    St. John's NL A1B 4J6
    Phone: 709-729-5019; 709-729-0115
    Fax: 709-729-0730
    Web site: http://www.health.gov.nl.ca/health/divisions/publichealth/default.htm
  • Nova Scotia
    Nova Scotia Health Promotion and Protection
    Summit Place, 6th Floor
    1601 Lower Water Street, P.O. Box 487
    Halifax, NS B3J 2R7
    Phone: 902-424-8160
    Fax: 902-424-0550
    Web site: http://www.gov.ns.ca/hpp/contact.html
  • Northwest Territories
    Office of the Chief Medical Health Officer
    Dept. of Health and Social Services
    Box 1320
    Yellowknife, NT X1A 2L9
    Phone: 867-920-8646
    Fax: 867-873-0442
    Web site: http://www.hlthss.gov.nt.ca/default.htm
  • Nunavut
    Office of the Chief Medical Health Officer
    Dept. of Health and Social Services
    Box 1000, Station 1000
    Iqaluit, Nunavut, X0A 0H0
    Phone: 867-975-5700
    Fax: 867-979-3190
  • Ontario
    Direct all forms to your local public health unit. Contact information for each health unit can be found on the following webpage:
    http://www.health.gov.on.ca/english/public/contact/phu/phuloc_mn.html
    Phone: PHD Info line 1-866-532-3161
    TTY: 1-800-387-5559
  • Prince Edward Island
    Office of Chief Health Officer
    Department of Health
    Box 2000
    Charlottetown, PEI C1A 7N8
    Tel: 902-368-4996
    Fax: 902-620-3354
    Web site: http://www.gov.pe.ca/health/index.php3
  • Quebec
    Phone: Call Info Santé in your region
    Web site: http://www.msss.gouv.qc.ca/sujets/santepub/vaccination/index.php?accueil_en
  • Saskatchewan
    Saskatchewan Health
    Population Health Branch
    3475 Albert Street
    Regina, SK S4S 6X6
    Phone: 1-800-667-7766
    Web site: http://www.health.gov.sk.ca/
  • Yukon
    Vaccine Program Manager
    Yukon Territorial Government
    Health & Social Services
    # 2 Hospital Road
    Whitehorse, YT Y1A 3H8
    Phone: (867) 667-8330
    Web site: http://www.hss.gov.yk.ca
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime